GlassScriptPhysician profile
Douglas P Williams
NPI 1528051208
$19,358.19
in general payments reported to CMS, 2019-2025
66 companies · $3,432 in 2025
The $3,432 reported for 2025 was more than what 81% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,244 · 2020: $1,409 · 2021: $1,959 · 2022: $2,755 · 2023: $3,173 · 2024: $3,386 · 2025: $3,432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,967 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,967.46 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,393.69 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Abbvie INC. | $1,453.20 | 2021-2025 | Qulipta, Ubrelvy, Duopa |
| Novartis Pharmaceuticals Corporation | $1,007.59 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $1,005.31 | 2019-2025 | Ultomiris, Soliris |
| Lilly USA, LLC | $952.91 | 2019-2025 | Emgality, Amyvid, Reyvow |
| Neurelis, INC. | $873.41 | 2020-2025 | Valtoco |
| Biogen, INC. | $738.98 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Lundbeck LLC | $710.52 | 2019-2025 | Vyepti, Rexulti |
| Mdd US Operations, LLC | $675.31 | 2019-2025 | Apokyn, Apokyn, Xadago |
| Genentech USA, INC. | $542.62 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Acadia Pharmaceuticals INC | $534.75 | 2019-2025 | Nuplazid |
| Allergan, INC. | $473.18 | 2019-2022 | |
| Tg Therapeutics, INC. | $448.28 | 2024-2025 | |
| Eisai INC. | $445.52 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $429.67 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.